AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson

Study start in the US and Europe confirmed for H2 2020VIENNA, AUSTRIA / ACCESSWIRE / January 27, 2020 / AFFiRiS AG, a clinical-stage biopharmaceutical company d